Home
MedDay

MedDay Market Share Analysis for June 2026

Industry: N/A

Domainmedday-pharma.com

Year Founded2011

Employees51 - 200

Annual Revenue$10M - $15M

MedDay

MedDay (including company regionals)

medday-pharma.com

See more website traffic and engagement information

MedDay Revenue up to June 2026 is 10M - 15M

revenue generated by MedDay top domains

MedDay top domains revenue over 3 years

Revenue for MedDay top domains

medday-pharma.com10M - 15M

See more with Sales Intelligence

Total visits to MedDay's top domains

Understand MedDay market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

medday-pharma.com136

See more with Sales Intelligence

Avg. visit duration in MedDay's top domains

Analyze MedDay engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

medday-pharma.com00:00:10

See more with Sales Intelligence

Avg. pageviews on MedDay's top domains

See how MedDay keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

medday-pharma.com2.29

See more with Sales Intelligence

MedDay top competitors by domain

Top similar sites in June 2026, ranked by their affinity

sofinnova.frCompany NameSofinnova Partners SASEmployees51 - 200HQFrance, ParisAnnual revenue$500M - $1BTotal visits--Finance > Accounting and Auditing

Top technologies used by MedDay

These are the website technologies, by industry, used by MedDay top domains

Widget (4)

Twemoji

Audio Video Media (3)

YouTube

Email Services (3)

SendinBlue

Mobile (2)

Meta Viewport

More Technologies

5

See all

News & Signals from MedDay

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMedDay acquired Profilomic on Mar 1st '17.For instance, in March 2017, MedDay acquired Profilomic’s (a company that provides biotechnology services) health division to enhance research capabilities.

NewsMedDay launches MED1003 failed.MedDay Pharmaceuticals announced its MED1003 failed to meet its primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis (MS).

NewsMedDay launched SPI2 on Nov 9th '18.MedDay Pharmaceuticals, an international pioneering biopharmaceutical company focusing on the development of products for the treatment of central nervous system disorders, today announced full enrollment of SPI2, a phase III clinical trial designed to confirm the potential of its investigational drug MD1003 in progressive MS as shown in MS-SPI phase III trial.